Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning. The FDA’s top drug regulator posted a highly unusual critique of a drug on his personal LinkedIn account yesterday that immediately got biotech investors talking and speculating. We’ll get into that below.
Skovronsky’s long-term vision for Eli Lilly
Eli Lilly’s chief scientific officer Dan Skovronsky sat down with my colleague Jonathan Wosen to talk about his R&D ambitions and how he thinks the company can maintain the momentum from its booming GLP-1 business.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
